Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. More Details
No risks detected for API from our risk checks.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Australian Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: API has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: API underperformed the Australian Healthcare industry which returned 0.8% over the past year.
Return vs Market: API underperformed the Australian Market which returned -8.9% over the past year.
Price Volatility Vs. Market
How volatile is Australian Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHave Insiders Been Buying Australian Pharmaceutical Industries Limited (ASX:API) Shares?
4 weeks ago | Simply Wall StAre Investors Undervaluing Australian Pharmaceutical Industries Limited (ASX:API) By 29%?
Is Australian Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: API (A$1.06) is trading below our estimate of fair value (A$1.32)
Significantly Below Fair Value: API is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: API is unprofitable, so we can't compare its PE Ratio to the AU Healthcare industry average.
PE vs Market: API is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate API's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: API is good value based on its PB Ratio (1.2x) compared to the AU Healthcare industry average (1.5x).
How is Australian Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: API is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: API is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: API's is expected to become profitable in the next 3 years.
Revenue vs Market: API's revenue is expected to decline over the next 3 years (-0.09% per year).
High Growth Revenue: API's revenue is forecast to decline over the next 3 years (-0.09% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: API's Return on Equity is forecast to be low in 3 years time (8.5%).
How has Australian Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: API is currently unprofitable.
Growing Profit Margin: API is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: API is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare API's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: API is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-8.1%).
Return on Equity
High ROE: API has a negative Return on Equity (-1.73%), as it is currently unprofitable.
How is Australian Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: API's short term assets (A$973.3M) exceed its short term liabilities (A$832.7M).
Long Term Liabilities: API's short term assets (A$973.3M) exceed its long term liabilities (A$252.5M).
Debt to Equity History and Analysis
Debt Level: API's debt to equity ratio (17.2%) is considered satisfactory.
Reducing Debt: API's debt to equity ratio has reduced from 18.9% to 17.2% over the past 5 years.
Debt Coverage: API's debt is well covered by operating cash flow (273.9%).
Interest Coverage: API is unprofitable, therefore interest payments are not well covered by earnings.
What is Australian Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: API's dividend (1.89%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.18%).
High Dividend: API's dividend (1.89%) is low compared to the top 25% of dividend payers in the Australian market (5.49%).
Stability and Growth of Payments
Stable Dividend: API's dividend payments have been volatile in the past 10 years.
Growing Dividend: API's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: API is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: API's dividends in 3 years are forecast to be covered by earnings (82.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard C. Vincent, B.Bus, (Accountancy), CPA, has been Chief Executive Officer, Managing Director and Executive Director at Australian Pharmaceutical Industries Limited since February 15, 2017. Mr. Vi ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD930.67K) is above average for companies of similar size in the Australian market ($USD700.61K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
|MD, CEO & Executive Director||3.67yrs||AU$1.30m||0.098% |
|Chief Financial Officer||5.75yrs||AU$592.46k||0.012% |
|Chief Information Officer||3.83yrs||no data||no data|
|General Counsel & Company Secretary||1.25yrs||no data||no data|
|General Manager of People||no data||AU$435.21k||no data|
|NSW State Manager||no data||AU$251.36k||no data|
Experienced Management: API's management team is considered experienced (3.8 years average tenure).
|MD, CEO & Executive Director||3.67yrs||AU$1.30m||0.098% |
|Interim Independent Non-Executive Chairman||0.083yr||AU$164.71k||0.0061% |
|Independent Non-Executive Director||12yrs||AU$130.97k||0.017% |
|Non-Executive Director||no data||no data||no data|
|Independent Non-Executive Director||2.92yrs||AU$140.19k||0.010% |
Experienced Board: API's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Australian Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
- Name: Australian Pharmaceutical Industries Limited
- Ticker: API
- Exchange: ASX
- Founded: 1910
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: AU$544.385m
- Shares outstanding: 492.66m
- Website: https://www.api.net.au
- Australian Pharmaceutical Industries Limited
- 250 Camberwell Road
- Level 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|API||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
|API||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails h ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/28 10:35|
|End of Day Share Price||2020/10/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.